

Coordinated β -globin expression and $\alpha 2$ -globin reduction in a multiplex lentiviral gene therapy vector for β -thalassemia

Tiwaporn Nualkaew,^{1,2,5,10} Karine Sii-Felice,^{3,4,10} Marie Giorgi,³ Bradley McColl,⁵ Julie Gouzil,³ Astrid Glaser,⁵ Hsiao P.J. Voon,⁶ Hsin Y. Tee,¹ George Grigoriadis,¹ Saovaros Svasti,^{2,7} Suthat Fucharoen,² Suradej Hongeng,⁸ Philippe Leboulch,^{3,9,11} Emmanuel Payen,^{3,4,11} and Jim Vadolas^{1,5,11}

¹Hudson Institute of Medical Research, Clayton, Melbourne, VIC 3168, Australia; ²Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand; ³Division of Innovative Therapies, CEA François Jacob Biology Institute, 18 route du Panorama, 92260, Fontenay-aux-Roses, France; ⁴Paris-Saclay University, CEA, INSERM, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92260 Fontenay-aux-Roses & Le Kremlin Bicêtre, France; ⁵Murdoch Children's Research Institute, Parkville, Melbourne, VIC 3052, Australia; ⁶Department of Biochemistry and Molecular Biology, Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; ⁷Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand; ⁸Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand; ⁹Genetics Division, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

A primary challenge in lentiviral gene therapy of β -hemoglobinopathies is to maintain low vector copy numbers to avoid genotoxicity while being reliably therapeutic for all genotypes. We designed a high-titer lentiviral vector, LV β -sh $\alpha 2$, that allows coordinated expression of the therapeutic β^{A-T87Q} -globin gene and of an intron-embedded miR-30-based short hairpin RNA (shRNA) selectively targeting the $\alpha 2$ -globin mRNA. Our approach was guided by the knowledge that moderate reduction of α -globin chain synthesis ameliorates disease severity in β -thalassemia. We demonstrate that LV β -sh $\alpha 2$ reduces $\alpha 2$ -globin mRNA expression in erythroid cells while keeping $\alpha 1$ -globin mRNA levels unchanged and β^{A-T87Q} -globin gene expression identical to the parent vector. Compared with the first β^{A-T87Q} -globin lentiviral vector that has received conditional marketing authorization, BB305, LV β -sh $\alpha 2$ shows 1.7-fold greater potency to improve α/β ratios. It may thus result in greater therapeutic efficacy and reliability for the most severe types of β -thalassemia and provide an improved benefit/risk ratio regardless of the β -thalassemia genotype.

Several lentiviral β -globin gene therapy vectors (LV β s) encompassing elements of the locus control region (LCR)⁴ are in clinical trials for β -hemoglobinopathies.^{5,6} Notably, the LentiGlobin BB305 gene therapy vector, encoding β^{A-T87Q} -globin, originally designed by Leboulch et al.⁷ and Pawliuk et al.⁸ to inhibit hemoglobin S (HbS) polymerization, has achieved clinical efficacy and safety in a large number of transfusion-dependent individuals with β -thalassemia^{9–12} and sickle cell disease in phase II and III trials.^{13,14} With regard to gene therapy for β -thalassemia, virtually all individuals with β -thalassemia with residual β -globin synthesis (non- β^0/β^0 genotype) (e.g., HbE/ β^0 -thalassemia), have discontinued transfusions following BB305 gene therapy, with near-normal blood Hb levels.^{9,11,12} Importantly, molecular and cellular hallmarks of dyserythropoiesis were corrected in individuals who achieved near-normal blood Hb values. As a result, autologous hematopoietic CD34⁺ cells transduced with BB305 are the first gene therapy product (Zynteglo) to be granted conditional approval in Europe for transfusion-dependent non- β^0/β^0 genotype individuals.¹⁵

INTRODUCTION

β -Thalassemia is the result of reduced or absent β -globin chain synthesis.^{1,2} During normal erythropoiesis, β -globin is synthesized in equimolar quantities with α -globin. Two chains of each protein associate to form the tetrameric adult hemoglobin (HbA; $\alpha_2\beta_2$). In β -thalassemia, a quantitative reduction or absence of β -globin chain synthesis disrupts the $\alpha:\beta$ -globin chain balance, leading to accumulation of unpaired α -globin in developing erythrocytes. Excess α -globin forms toxic aggregates, causing apoptosis of immature red blood cells (RBCs).³ The most severe forms of β -thalassemia manifest as dyserythropoiesis and hemolytic anemia, requiring monthly blood transfusions and lifelong iron chelation therapy.

Received 17 August 2020; accepted 27 April 2021;
<https://doi.org/10.1016/j.ymthe.2021.04.037>.

¹⁰These authors contributed equally

¹¹These authors contributed equally

Correspondence: Jim Vadolas, Hudson Institute of Medical Research, Clayton, Melbourne, VIC 3168, Australia.

E-mail: jim.vadolas@hudson.org.au

Correspondence: Emmanuel Payen, Division of Innovative Therapies, CEA François Jacob Biology Institute, 18 route du Panorama, 92260, Fontenay-aux-Roses, France.

E-mail: emmanuel.payen@cea.fr

Correspondence: Philippe Leboulch, Genetics Division, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

E-mail: leboulch@rics.bwh.harvard.edu



However, β^0/β^0 -genotype individuals have been proven to be more challenging to treat with BB305 gene therapy.^{9–12} Only a subset of β^0/β^0 -genotype individuals achieved transfusion independence, although most displayed a decrease in transfusion requirements.^{9,10,12,16} The clinical efficacy of lentiviral β -globin gene therapy vectors is directly correlated with the number of proviral integration events in hematopoietic cells and overall output of therapeutic β -globin chain synthesis.^{11,17} Achieving an optimal therapeutic effect in all β^0/β^0 -genotype individuals, who have the greatest requirement for therapeutic β -globin output, would benefit from a lentiviral vector capable of minimizing the detrimental effects of free α -globin chains while continuing to express high levels of β^{A-T87Q} -globin in an erythroid-specific manner. Such a combination vector would theoretically result in greater therapeutic efficacy and reliability at lower vector copy numbers (VCNs) than BB305. Reaching the therapeutic threshold at lower VCNs would reduce the risk of untoward insertional mutagenesis for all individuals with β -thalassemia regardless of genotype.

To enhance the therapeutic efficacy of the BB305 gene therapy vector for the most severe β^0/β^0 -genotype individuals, we developed a novel multiplexed lentiviral β -globin gene vector that allows coordinated expression of the therapeutic β^{A-T87Q} -globin gene with concomitant reduction in α -globin chain synthesis. Our approach was guided by the knowledge that co-inheritance of an α -thalassemia trait along with a variety of β -thalassemia mutations reduces the clinical severity of β -thalassemia. A single α -globin gene deletion ($-\alpha/\alpha$) has a minimal effect, but double ($-\alpha/-\alpha$ or $-/\alpha\alpha$) or triple ($-/-\alpha$) α -globin gene deletions have a major beneficial effect on disease severity by normalizing α : β -globin chain balance and minimizing the harmful effects of free α -globin chains.^{18–21}

Here we modified LentiGlobin BB305 by inserting a miR-30 short hairpin RNA (shRNA) expression cassette into intron 2 of the β^{A-T87Q} -globin gene to derive the LV β -shRNA vector, allowing stable erythroid-specific expression of functional shRNA from a common primary transcript. We further configured the LV β -shRNA vector to specifically target the human $\alpha 2$ -globin (*HBA2*) mRNA to generate the LV β -sh $\alpha 2$ gene therapy vector. We demonstrate that the LV β -sh $\alpha 2$ vector yields a high viral titer, transduction efficiency, and erythroid β^{A-T87Q} -globin gene expression equivalent to the parent BB305 vector. Notably, LV β -sh $\alpha 2$ shows the additional property of decreasing human $\alpha 2$ -globin mRNA levels without affecting $\alpha 1$ -globin (*HBA1*) mRNA expression levels in transduced human erythroid cell lines and primary human CD34⁺ hematopoietic cells derived from normal individuals and those with β -thalassemia. Importantly, the LV β -sh $\alpha 2$ vector is able to achieve a greater degree of correction of α : β -globin mRNA ratios in cells from individuals with β -thalassemia at identical VCNs compared with the parent BB305. We define a novel therapeutic strategy that could improve gene therapy outcomes in individuals with β -thalassemia irrespective of genotype.

RESULTS

Generation of the LV β gene therapy vector carrying a functional intron-encoded miR30-shRNA expression cassette

To examine whether the LentiGlobin BB305 vector could be used to deliver miR30-shRNA expression cassettes embedded in an intron of

the vector-bearing β^{A-T87Q} -globin gene (Figure 1A; Figure S1), LV β -shRNA vectors carrying the enhanced green fluorescent protein (EGFP)-specific shRNA (LV β -shGFP) and scrambled negative control (LV β -shSCR) vectors were generated and validated in the murine erythro-leukemia (MEL)- β EGFP reporter cell line, in which EGFP expression is driven by the human β -globin promoter in the context of a chromosomally integrated, large segment of the human β -globin locus.^{22,23} Following viral transduction with BB305, LV β -shSCR, and LV β -shGFP vectors, bulk-transduced MEL- β EGFP cells were induced to undergo erythroid differentiation after exposure to dimethyl sulfoxide (DMSO). We observed that LV β -shGFP significantly reduced EGFP fluorescence and mRNA expression, whereas BB305 and LV β -SCR vectors had no significant effect (Figures 1B and 1C).

Next, β^{A-T87Q} -globin mRNA expression was measured following erythroid differentiation of the transduced MEL- β EGFP cells. We observed that β^{A-T87Q} -globin transgene expression by the LV β -shGFP and LV β -shSCR vectors was equivalent to the parent BB305 vector (Figure 1D). To assess whether the miR30-shRNA expression cassette may yield alternative or aberrant mRNA splicing events, β^{A-T87Q} -globin expression was analyzed by RT-PCR using primers located on either side of the human β^{A-T87Q} -globin exon 2-3 boundary (Figure S2A). A single PCR product of the expected size (168 bp), representing the correctly spliced β^{A-T87Q} -globin mRNA, was identified in cells transduced with the BB305, LV β -shSCR, and LV β -shGFP vectors (Figure S2B). These results indicate that inserting the miR30-shRNA expression cassette at the intervening sequence 2 (IVS2) breakpoint site allows normal mRNA splicing and does not result in aberrant splice products detected by the assay.

To investigate the relationship between β^{A-T87Q} -globin transgene expression and functional EGFP shRNA, transduced MEL- β EGFP clones ($n = 10$) were analyzed following erythroid differentiation. Consistent with the bulk-transduced cells, the LV β -shGFP vector significantly diminished EGFP fluorescence in individual clones (Figure 1E). In LV β -shGFP-transduced clones, EGFP shRNA and β^{A-T87Q} -globin transgene expression levels showed a significant positive correlation between them ($p < 0.0001$) (Figure 1F), whereas β^{A-T87Q} -globin transgene expression levels and EGFP fluorescence displayed a significant negative correlation ($p = 0.0005$) (Figure 1G). As expected, there was no correlation between β^{A-T87Q} -globin expression and EGFP fluorescence in BB305- or LV β -shSCR-transduced clones ($p = 0.7811$) (Figure 1H). These results demonstrate that the LV β -shGFP vector produces a functional intron-encoded shRNA whose amount depends on the expression level of the β^{A-T87Q} -globin transgene.

Validation in K562 cells of LV β -shRNA lentiviral vectors tailored to reduce human α -globin expression

We then explored the possibility of using small interfering RNAs (siRNAs) to reduce human α -globin gene expression. Comparative analysis of 5 siRNAs targeting different α -globin locations was performed following electroporation into K562 cells. Four siRNAs




Figure 1. The LVβ gene therapy vector containing intronic miR30-shGFP reduces target gene expression in erythroid cells

(A) Schematic of the LVβ gene therapy vector, LentiGlobin BB305, modified to express the miR30-shRNA cassette. (B) Representative histograms of EGFP expression by MEL-βEGFP cells transduced with the BB305, LVβ-shSCR, and LVβ-shGFP vectors at equivalent MOIs. (C and D) Relative EGFP mRNA expression (C, n = 3) and β^{A-T87Q}-globin mRNA expression (D) in transduced MEL-βEGFP cells normalized to β-actin. Data are presented as mean ± SD of at least three separate experiments relative to untransduced (UT) cells following 10 days of DMSO induction. Significance was calculated by unpaired Student's t test; *p ≤ 0.05, ***p ≤ 0.001. (E) Flow cytometry analysis of individual MEL-βEGFP clones (n = 10) transduced with the BB305, LVβ-shSCR, and LVβ-shGFP vectors. Data represent median (lines), the 25th and 75th percentiles (boxes), and the 90th and 10th percentiles (error bars) (**p ≤ 0.0001). (F–H) Correlation analysis of (F) shGFP expression to β-globin mRNA, (G) EGFP fluorescence to β-globin mRNA in LVβ-shGFP-transduced clones, and (H) EGFP MFI to β-globin mRNA in BB305-transduced (squares) and LVβ-shSCR-transduced (circles) clones following 10 days of DMSO induction. Correlation analysis was performed using the Spearman rank method. Scatterplot linear regression lines with 95% confidence intervals (dotted lines) are displayed for (F)–(H). A positive correlation between shGFP expression and β-globin mRNA expression in LVβ-shGFP clones was detected (n = 18, R = 0.864, p < 0.0001). A negative correlation between EGFP MFI and LV β-shGFP β-globin mRNA expression was detected (n = 18, R = -0.735, p < 0.0005). EGFP MFI and β-globin mRNA expression in BB305-transduced (squares) and LVβ-shSCR-transduced (circles) clones did not correlate (n = 16, R = 0.0751, p = 0.7811).




Figure 2. The LV β gene therapy vector containing the miR30-shRNA expression cassette can be used to reduce α -globin expression in K562 cells

(A) Schematic of α -globin mRNA showing the location of the sh $\alpha 1/2$ and sh $\alpha 2$ target sites. (B) Relative $\alpha 1$ and $\alpha 2$ -globin mRNA expression levels in K562 cells transduced with the BB305, LV β -shSCR, LV β -sh $\alpha 1/2$, and LV β -sh $\alpha 2$ vectors at equivalent MOIs following 5 days of hemin induction. $\alpha 1/\alpha 2$ -globin mRNA expression levels were calculated by normalizing to β -actin in UT controls. (C) Representative western blot analysis of K562 cells transduced with the BB305, LV β -shSCR, LV β -sh $\alpha 1/2$, and LV β -sh $\alpha 2$ vectors following hemin induction. (D and E) Relative quantification of (D) α -globin and (E) β -globin chains. The level of β -actin expression in UT cells was used to normalize signal intensity values between samples. Data represent mean \pm SD of three independent experiments and vector preparations. Statistical analysis was performed using unpaired Student's *t* test (**p* \leq 0.05, ***p* \leq 0.01, ****p* \leq 0.001).

were identified to significantly reduce human α -globin mRNA (Figure S3). Because si- $\alpha 3$ and si- $\alpha 4$ showed a suitable reduction in human α -globin expression, they were configured into the LV β -shRNA vector system to generate the LV β -sh $\alpha 1/2$ and LV β -sh $\alpha 2$ vectors, respectively. Because of a number of nucleotide differences between human $\alpha 1$ and $\alpha 2$ globin mRNAs in their 3' untranslated regions (UTRs), the LV β -sh $\alpha 2$ was designed to specifically target human $\alpha 2$ -globin mRNA without affecting human $\alpha 1$ -globin mRNA, whereas LV β -sh $\alpha 1/2$ targets the third exon of the $\alpha 1$ -globin and $\alpha 2$ -globin genes (Figure 2A). LV β -shRNA vectors yielded titers equivalent to that of the parental BB305 vector (Figure S4).

The human α -globin-specific mRNA knockdown activity of the LV β -sh $\alpha 1/2$ and LV β -sh $\alpha 2$ vectors was evaluated in K562 cells by qRT-PCR analysis (Figure 2B). The LV β -sh $\alpha 1/2$ vector reduced $\alpha 1$ - and $\alpha 2$ -globin mRNA by approximately 50%. Notably, the LV β -sh $\alpha 2$ vector reduced $\alpha 2$ -globin mRNA expression by $78\% \pm 13\%$ (*p* < 0.001), whereas $\alpha 1$ -globin mRNA remained unaffected (Figure 2B). Using primers designed to amplify across the exon 2-to-exon 3 junction, the correctly spliced human β^{A-T87Q} -globin mRNA was detected as a single RT-PCR product (168 bp) (Figure S2C). Importantly, western blot analysis of proteins extracted from transduced K562 cells confirmed a substantial reduction of α -globin chain expression by the LV β -sh $\alpha 1/2$ and LV β -sh $\alpha 2$ vectors ($35\% \pm 15\%$ and $30\% \pm 18\%$, respectively; *p* < 0.05) compared with negative control groups (Figures 2C and 2D), whereas β -globin expression remained unchanged at the mRNA and protein levels (Figures 2C and 2E). To ensure that the α -globin knockdown would not be complete, we decided to focus on the LV β -sh $\alpha 2$ vector, which specifically targets the $\alpha 2$ -globin mRNA, leaving $\alpha 1$ -globin expression untouched.

The LV β -sh $\alpha 2$ lentiviral vector reduces $\alpha 2$ -globin expression in β^0 -HUDEP-2 cells

The HUDEP-2 cell line recapitulates the human adult erythroid differentiation program.²⁴ To evaluate LV β -shRNA vectors in a sustain-

able β -thalassemia environment, a HUDEP-2 cell line containing biallelic β^0 -globin mutations, β^0 -HUDEP-2, was created using CRISPR-Cas9 genome editing (Supplemental materials and methods). The absence of β -globin chain synthesis was confirmed by high performance liquid chromatography (HPLC) analysis (Figure 3C). β^0 -HUDEP-2 cells failed to progress beyond the Poly-E stage of differentiation and morphologically exhibited an increased level of cell death by day 8, recapitulating the β -thalassemia environment (Figures 3A and 3B).

We next evaluated erythroid maturation of β^0 -HUDEP-2 cells following transduction with the BB305, LV β -shSCR, and LV β -sh $\alpha 2$ vectors at equivalent multiplicities of infection (MOIs). Initial transduction efficiency, as measured by intracellular β -globin staining 48 h after transduction, ranged from 27.0%–40.7%, and after one cryopreservation cycle, the majority of transduced β^0 -HUDEP-2 cells ($88.3\% \pm 6.0\%$) expressed the β^{A-T87Q} -globin transgene (data not shown). Therefore, β^{A-T87Q} -globin transgene expression appears to provide a survival advantage in bulk-transduced β^0 -HUDEP-2 cells. This is in agreement with the observations made by Miccio et al.,²⁵ who have reported a selective survival advantage of genetically corrected β -thalassemic erythroid progenitor cells in mice. A similar survival advantage because of β^{A-T87Q} -globin transgene expression was also observed during a 10-day time course of erythroid differentiation with β^0 -HUDEP-2 cells transduced with the BB305, LV β -shSCR, or LV β -sh $\alpha 2$ vector (Figure 3D). Morphological analysis of β^0 -HUDEP-2 cells transduced with the BB305, LV β -shSCR, or LV β -sh $\alpha 2$ vector revealed a significant reduction in the proportion of Baso-E and a concomitant increase in Ortho-E, which was equivalent to normal HUDEP-2 cells (Figures 3A and 3B). Importantly, these results demonstrate that β^{A-T87Q} -globin transgene expression by either of the three vectors is sufficient to restore β^0 -HUDEP-2 erythroid maturation to the normal range.

Next, β^0 -HUDEP-2 cells were transduced at two different MOIs to result in low and high VCNs (1–2 and 12–15), and α - and β -globin




Figure 3. Analysis of β^0 -HUDEP-2 differentiation following transduction with the LV β -sh α 2 lentiviral vector

(A) Morphological changes of HUDEP-2 and β^0 -HUDEP-2 cells following differentiation. Day 0, day 4, and day 8 samples were stained with May-Grünwald Giemsa. Arrows indicate advanced stages of erythroid differentiation (Ortho-E, Poly-E, and Baso-E are indicated on day 4 and day 8). Magnification: 1,000 \times ; scale bars, 25 μ m. (B) Erythroid progenitor populations on day 0, day 4, and day 8 of differentiation. Cells at different stages of differentiation were counted from images taken at 400 \times magnification from cytospin slides. Percentages of different erythroid populations (Ortho-E, Poly-E, and Baso-E) for day 4 and day 8 of differentiation are shown (n = 2, >200 cells counted per cytospin). (C) Hemoglobin variant analysis by HPLC of the soluble cellular fraction obtained from HUDEP-2 and β^0 -HUDEP-2 cells transduced with BB305, LV β -shSCR, and

(legend continued on next page)

mRNA expression levels were assessed by qRT-PCR analysis during the expansion phase. Remarkably, the LV β -sh α 2 vector reduced α 2-globin transcription levels by more than 3- and more than 20-fold, respectively, compared with that observed in untreated and BB305- and LV β -shSCR-transduced β^0 -HUDEP-2 cells (Figure S5). Accordingly, the reduction in α 2-globin mRNA was reflected in the reduction of the α 2/ α 1-globin mRNA ratio (by up to ~95%) by the LV β -sh α 2 vector, whereas α 1-globin mRNA levels were equivalent in BB305- and LV β -shSCR-transduced β^0 -HUDEP-2 cells (Figure 3E; Figure S5). Similarly, α - to β -globin mRNA ratios in LV β -sh α 2-transduced cells decreased by approximately 25% (1–2 VCNs) and 50% (12–15 VCNs) (Figure S5). Because unpaired α -globin chains precipitate and are thus excluded from the water-soluble protein fraction, we also prepared the water-insoluble fraction for globin chain examination. Western blot analysis demonstrated reduced levels of α -globin chains in the water-insoluble cell fraction of β^0 -HUDEP-2 cells transduced with BB305, LV β -shSCR, or LV β -sh α 2. This was the result of a greater degree of α -globin chain assembly into hemoglobin complexes resulting from β^{A-T87Q} -globin transgene expression from BB305 and LV β -shSCR. In the case of β^0 -HUDEP-2 cells transduced with LV β -sh α 2, the amount of α -globin chain in the water-insoluble fraction was further reduced to normal levels through the combined effects of β^{A-T87Q} -globin transgene expression and decreased α 2-globin chain synthesis (Figure 3F).

LV β -sh α 2 normalizes α / β -globin mRNA ratios in primary human erythroid cells from individuals with β -thalassemia by decreasing α 2-globin mRNA levels


CD34⁺ cells from human cord blood (CB) and individuals with β -thalassemia (n = 2) were transduced at clinically relevant VCNs with the BB305, LV β -shSCR, or LV β -sh α 2 vector (Figure S6). We chose to perform experiments in cells from individuals with HbE/ β -thalassemia because use of non-transduced β^0/β^0 cells would not have provided a negative control for α/β mRNA ratios following vector transduction because this cell population does not properly differentiate and survive during *in vitro* erythroid differentiation.²⁶ Furthermore, transduction of cells from individuals with β^0/β^0 -thalassemia with β -globin gene expressing vectors is sufficient to rescue erythroid cell proliferation and differentiation *in vitro*, indistinguishably from normal cells.²⁶ Thus, a reduction in the α/β mRNA ratio by co-expression of α -globin-specific shRNAs would not produce further observable phenotypic correction *in vitro*.

Erythroid differentiation profiles of transduced CD34⁺ cells were determined by measuring the percentages of erythroid precursor cells (Figure 4A). Following erythroid differentiation, no gross differences were found between transduced erythroblasts based on the cell surface expression profiles of erythroid markers (Figure 4B). The cell sur-

face expression profile of glycophorin A (GPA)⁺ cells followed the generally accepted differentiation dynamics with CD36 and CD71 cell surface expression already present on erythroblasts, increasing during differentiation but decreasing at the end of differentiation. The final stages of differentiation were associated with a reduction in cell volume, as seen by a decrease in forward scatter (FSC) (Figure 4A). These data indicates that the LV β -shSCR or LV β -sh α 2 vectors were not associated with any deleterious effects on erythroid differentiation, as assessed over 21 days of culture.

We next measured the mRNA ratios of α /(β -like)-globins (i.e., α /($\beta^E + \beta^{A-T87Q} + \gamma^A + \gamma^G$)) in erythroid cells obtained by culture of CD34⁺ cells from CB of a normal individual and from bone marrow of an individual with HbE/ β -thalassemia following transduction with the BB305, LV β -shSCR, or LV β -sh α 2 vector (Figure 4C). The γ -globin mRNAs were quantified only when CB cells were included in the comparison. As expected, the α /(β -like)-globin mRNA ratios in the absence of vector transduction were higher in HbE/ β -thalassemia cells than in normal CB cells (Figure S7A) because of the β -thalassemia phenotype. Either of the control vectors (BB305 or LV β -shSCR) led to partial normalization of the α /(β -like)-globin mRNA ratios because of expression of β^{A-T87Q} -globin gene (Figures S7B and S7C). Furthermore, when α /(β -like)-globin mRNA ratios were gathered at different time points during erythroid differentiation culture, normalized to ratios in non-transduced cells, and plotted for comparison between BB305 and LV β -shSCR, no difference was observed (Figures S7B and S7C), indicating that the miR30-shRNA expression cassette does not interfere with vector-derived or endogenous β -like-globin expression levels. This allowed us to pool data collected for BB305 and LV β -shSCR-transduced cells to form a single control group for statistical comparison with data obtained with LV β -sh α 2-transduced cells (Figure 4C). Most significantly, LV β -sh α 2 reduced α /(β -like)-globin mRNA ratios in adult HbE/ β -thalassemia erythroid cells to levels seen with normal CB cells (Figure 4C), whereas BB305- and LV β -shSCR-transduced cells had less of an effect on α /(β -like)-globin mRNA ratios, particularly during the final stages of erythroid differentiation (day 18). Importantly, these results were obtained at similar VCNs (Figure 4D). We then set out to quantify differences between vector groups in the erythroid cell population of transduced and cultured CD34⁺ marrow cells from 2 adults with HbE/ β -thalassemia (P1 and P2). The (α/β -like)-globin mRNA ratios decreased by 2.34- and 1.25- fold with LV β -sh α 2 versus the control BB305/LV β -shSCR group at mean VCN levels of approximately 3 and 0.75 for P1 and P2, respectively (Figure S8). Importantly the vector encoded β^{A-T87Q} -globin chain was detected at similar levels with all three vectors (Figure S9), supporting the conclusion that variation of the α/β ratio is solely due to α -globin mRNA reduction in cells transduced with the LV β -sh α 2 vector.

LV β -sh α 2 on day 10 of erythroid differentiation. (D) Cumulative cell index of HUDEP-2, β^0 -HUDEP-2, and β^0 -HUDEP-2 cells transduced with the BB305, LV β -shSCR, and LV β -sh α 2 vectors over a 10 day time-course of erythroid differentiation. Data are presented as mean \pm SD of two independent experiments. (E) Relative α 2/ α 1-globin mRNA expression levels in HUDEP-2, β^0 -HUDEP-2, and β^0 -HUDEP-2 cells transduced with the BB305, LV β -shSCR, and LV β -sh α 2 vectors. (F) Western blot analysis of soluble and membrane fractions of HUDEP-2, β^0 -HUDEP-2, and transduced β^0 -HUDEP-2 cells after 10 days of erythroid differentiation. The antibody used for β -globin detection cross-reacts with δ -globin and therefore contributes to the faint band observed with β^0 -HUDEP-2 cells.



(legend on next page)

With regard to differences between the 2 α -globin species, the mean $\alpha 2/\alpha 1$ -globin mRNA ratio after BB305/LV β -shSCR transduction was equivalent to that measured in non-transduced cells. In contrast, $\alpha 2/\alpha 1$ -globin mRNA ratios were 3.52- and 2.21-fold lower with LV β -sh $\alpha 2$ than with the control vectors in P1 and P2, respectively (Figure 4E). We then plotted $\alpha 2/\beta$ -globin mRNA ratios relative to $\alpha 1/\beta$ -globin mRNA ratios in the various groups (Figure 4F; Figure S8). As expected, the regression line obtained after transduction with the control vectors BB305/LV β -shSCR fit the data points for untransduced cells. The slope of the regression line for LV β -sh $\alpha 2$ -transduced cells was significantly lower than the slope for the control vectors ($p < 0.001$), indicating that the decreased $\alpha 2/\alpha 1$ -globin mRNA ratio is caused by a decrease in $\alpha 2$ -globin mRNA levels and not by an increase in $\alpha 1$ -globin mRNA levels.

LV β -sh $\alpha 2$ improves (α/β)-globin mRNA ratios at lower VCNs compared with BB305

We next measured (α/β -like)-globin mRNA ratios relative to VCN in P1 and P2 after transduction with the different vectors (Figure 5A). CD34⁺ cells were transduced at different MOIs (Figure S6). The (α/β -like)-globin mRNA ratios in BB305- and LV β -shSCR-transduced cells were inversely correlated to the VCNs (Figures S7B and S7C), and these mRNA ratios (y axis) as a function of VCN values (x axis) best fit an “exponential decay model” (Figure S10). No significant difference was observed between the decay rate constants K for BB305 and LV β -shSCR, indicating that β -globin transgene expression levels were equivalent within this control vector group. In contrast, transduction of HbE/ β -thalassemia cells with the LV β -sh $\alpha 2$ vector decreased α/β -globin mRNA ratios to a greater degree than with the vector control group for a given VCN value (Figure 5B), yielding differential values for K. The mean VCNs were 2.8 and 3.1 for BB305/LV β -shSCR- and LV β -sh $\alpha 2$ -transduced P1 cells, respectively, and 0.81 and 0.66 for BB305/LV β -shSCR- and LV β -sh $\alpha 2$ -transduced P2 cells, respectively (Figure S8). According to the model, the relative fold decreases in (α/β -like) ratios with the LV β -sh $\alpha 2$ vector compared with the control vector group, calculated from the best fit curves, were 2.16 ($e^{(3.1 \times 0.5211) - (2.8 \times 0.3013)}$) and 1.25 ($e^{(0.66 \times 1.282) - (0.81 \times 0.7705)}$) in samples from P1 and P2, respectively (Figure 5B). These calculated values were comparable with the actual measures of 2.34 and 1.25 for P1 and P2, respectively (Figure S8), suggesting that the model fits the data well. The model takes into account all relevant parameters, which include α -globin mRNA fold reduction by the shRNAs, increased β -like-globin mRNA production because of vector-derived β^{A-T87Q} -globin expression, and VCN levels.

An important corollary to the model is that one can derive the “gain” in VCN values between the LV β -sh $\alpha 2$ vector and the control vector group to achieve the same degree of normalization (decrease) of the (α/β -like)-globin mRNA ratios, establishing the differential potency of the various vectors. This is obtained by simply calculating the ratio of the K decay rate constants for each of the two groups, and the factor so derived is 1.7. Importantly, this determination is independent of VCN levels. In other words, 1.7-fold fewer integrated vector copies of the LV β -sh $\alpha 2$ vector than the parent vector BB305 are sufficient to achieve the same degree of (α/β -like)-globin mRNA ratio improvement.

To further validate the LV β -sh $\alpha 2$ vector, we investigated a third individual with β^0/β^+ -thalassemia (P3) with a particularly severe compound heterozygous genotype (IVS2-654C > T and -28A > G). We also made use of pooled erythroid colonies grown in methylcellulose instead of liquid cultures, used previously for P1 and P2, to diversify the experimental approach. CD34⁺ cells were transduced at a low MOI to maximize the number of cells with a single integration event. After transduction ($n = 2$), cells were grown in methylcellulose for 2 weeks and analyzed by qPCR for VCN determination and concurrent globin mRNA assays by qRT-PCR. The mean population VCNs were 0.23, 0.77, and 0.80 for LV β -shSCR-, BB305-, and LV β -sh $\alpha 2$ -transduced cells, respectively (Figure 6A). Again, the LV β -sh $\alpha 2$ vector showed a greater potency to decrease α/β -globin mRNA ratios than BB305 at low VCNs (Figure 6B).

DISCUSSION

In this study, we report an innovative gene therapy strategy and vector to improve the clinical efficacy and safety of current lentiviral gene therapy for individuals with β -thalassemia. The gene therapy vector derived from BB305 comprises the therapeutic anti-sickling β^{A-T87Q} -globin gene configured with an intronic miR30-shRNA tailored to quantitatively reduce α -globin chain synthesis and correct the $\alpha:\beta$ -globin chain imbalance. LV β -sh $\alpha 2$ was designed to specifically target human $\alpha 2$ -globin mRNA without affecting human $\alpha 1$ -globin mRNA. This ensures that there will be no risk of inducing clinically meaningful α -thalassemia.

Our results demonstrate that LV β -sh $\alpha 2$ vector titers and transduction efficiency in primary human hematopoietic CD34⁺ cells are equivalent to the parent BB305 gene therapy vector. LV β -sh $\alpha 2$ retains vector-encoded β^{A-T87Q} -globin expression profiles similar to BB305 in erythroid cell lines and erythroid progeny of transduced normal and β -thalassemia CD34⁺ cells. The reduction in $\alpha 2$ -globin mRNA levels, in concert with vector-encoded β^{A-T87Q} -globin expression,

Figure 4. Analysis of LV β -sh $\alpha 2$ -mediated knockdown of $\alpha 2$ -globin in primary erythroid cells

(A) Erythroid differentiation profile of cells from P1 grown in medium 1 after transduction with BB305, LV β -shSCR, or LV β -sh $\alpha 2$ at equivalent MOIs. (B) Mean percentages of populations 1 (CD71^{hi}/CD36^{hi}), 2 (CD71^{hi}/CD36^{med}), and 3 (CD71^{med}/CD36^{lo}) in GPA⁺ cells. (C) Analysis of ($\alpha/(\beta+\gamma)$)-globin mRNA ratios in CB and P1 cells transduced with the BB305, LV β -shSCR, and LV β -sh $\alpha 2$ vectors. Results from BB305 and LV β -shSCR were pooled. (D) VCNs in the samples analyzed in (C). Data are presented as mean \pm SD of three replicates (E) Analysis of $\alpha 2/\alpha 1$ -globin mRNA ratios in cells from 2 individuals with HbE/ β -thalassemia (P1 and P2). For each analyzed sample, ratios were normalized to those measured at the same time point in non-transduced cells. (F) Correlation between $\alpha 2/\beta$ -globin and $\alpha 1/\beta$ -globin mRNA ratios in erythroid cells of P1 (days 11, 14, and 16) and P2 (days 11, 15, 18, and 21).




Figure 5. Analysis of α/β -globin ratio to VCN in transduced primary HbE/ β -thalassemia erythroid cells

(A) α/β -globin mRNA ratio in transduced primary cells from two individuals (P1 and P2) with HbE/ β -thalassemia. Cells were transduced at MOI 5 and 10 (P1) or 1 and 3 (P2) and grown for 3 weeks in medium 1 (P1) or medium 2 (P2). (B) Curve fitting to normalized data, 95% confidence intervals, and significance of differences between decay rates (K) calculated from data obtained in BB305/LV β -shSCR- and LV β -sh α 2-transduced cells. Results from day 18 in (A) were not included to construct the best fit curve because the data did not follow the shared model. Determination of p values for comparison of decreased rates in samples transduced with the BB305/LV β -shSCR and LV β -sh α 2 vectors was performed, assuming ratios of 1 in unmodified cells and 0 at infinite VCN.

improved α/β -globin ratios in β -thalassemia erythroid cells to the same degree at VCN levels 1.7-fold lower than those of the parent vector BB305. Importantly, α 1-globin mRNA levels are unaffected.

Although BB305 has proven highly effective and reliable for successful treatment of β^+ -thalassemia (e.g., HbE/ β^0 -thalassemia), it has faced more challenges for individuals with a β^0/β^0 genotype because of the very large amount of therapeutic protein that needs to be produced *in vivo* in this population.^{10,11} Preliminary data from a recent clinical trial of BB305 that focuses on individuals with β^0/β^0 -thalassemia (HGB-212) indicate that higher levels of hematopoietic stem cell (HSC) transduction were able to increase Hb levels to 13.2 g/dL in one individual and to 10.4 g/dL, respectively, in two individuals with the β^0/β^0 genotype after 12 months of follow-up.^{10,27} Although these clinical data are encouraging, there is room for further improvement in this challenging population. Although continuous optimization in transduction conditions may play a major role in increasing clinical efficacy, further augmenting VCN values in hematopoietic cells raises the concern of an increased risk of oncogenicity by insertional mutagenesis.^{27,28}

Previous efforts to increase β -globin gene synthesis explored the use of larger DNase hypersensitive site (HS) fragments or adding the LCR HS 1 (HS1) element in LV β gene therapy vectors, and this provided only modest improvements.^{29,30} The use of chromatin insulators, such as the chicken β -globin locus 5' HS4 element, has also been explored to prevent the repressive influences of surrounding chromatin on the integrated vector and reduce possible *cis*-acting effects of the LCR enhancers on neighboring genes.^{31,32} However, these elements were associated with reduced transduction efficiency and genetic instability.^{33,34}

Clinical evidence indicates that moderate reduction of α -globin chains via co-inheritance of the α -thalassemia trait decreases the severity of β -thalassemia.^{19,35} Decreasing the levels of unpaired α -globin has been proposed on a theoretical basis as a complementary approach for treatment of β -thalassemia.^{18,36–38} Our previous investigations demonstrated phenotypic improvement of primary erythroid cells derived from β -thalassemic mice (Hbb^{th3/+}) when treated with α -globin-specific siRNA.²¹ However, lifelong delivery of siRNAs are a major limitation for the utility of therapeutic




Figure 6. Analysis of α/β -globin ratios in transduced primary β^0/β^+ -thalassemia erythroid cells

CD34⁺ cells from a transfusion-dependent individual with β^0/β^+ -thalassemia were transduced ($n = 2$) with the BB305, LV β -shSCR, and LV β -shz2 vectors at low MOI, grown in methylcellulose for 2 weeks, and analyzed by qPCR, qRT-PCR, and HPLC for VCN determination and globin gene expression. (A) Correlation of the $\beta^{\text{T}87\text{Q}}$ -globin chain fraction relative to VCN. (B) α/β -mRNA ratios relative to UT cells.

siRNAs for β -hemoglobinopathies. Approaches based on transduction of HSCs with LV vectors harboring shRNAs are an effective delivery strategy for clinical translation of RNAi-based therapies. Such a strategy was used to deliver a sickle (β^{S})-globin-specific shRNA embedded in intron 2 of the γ -globin gene because a moderate decrease in β^{S} -globin expression may substantially improve sickle cell disease and abrogate the need for high-level expression of the vector-encoded globin gene.³⁹

More recently, by extending the design principles of microRNAs (miRNAs), an optimized BCL11A-shRNA embedded in a miRNA was used to achieve ubiquitous knockdown of BCL11A and promote production of HbF in erythroid cells.^{40,41} Utilizing the erythroid-specific β -globin LCR to drive expression of a miRNA-containing BCL11A-specific shRNA and minimize potential off-target side effects averted negative effects on HSC engraftment.^{42–44} Similarly, LV vectors encoding erythroid-specific shRNA were designed to target the aberrant mRNA in $\beta^{\text{IVS1-110}}$ -thalassemia because it may potentially interfere with *HBB* expression.⁴⁵ These findings signify the importance of lineage-specific gene silencing because it can be used as a flexible tool for analysis of gene function and development of gene-specific therapeutic agents.

The strategy to combine β -globin gene addition with reduction of α -globin chains has been evidenced previously using foamy virus vector-expressing β -globin regulated by the HS40 element derived from the α -globin locus and polymerase III (Pol III)-directed, α -globin-specific shRNA.⁴⁶ This vector has been reported to restore globin chain balance in β^0 -thalassemic erythroid cells. However, lack of proper control and the deleterious effect of Pol III-directed shRNA limits its use.⁴⁶ An alternative approach to reduce α -globin expression, focused on disrupting the core α -globin gene enhancer MCS-R2 (HS-40) in primary human HSCs using genome editing technology.⁴⁷ This strategy was used to emulate a natural α -thalassemia mutation and reduce α -globin expression to levels beneficial for individuals with β -thalassemia. In cells with HbE/ β -thalassemia mutations,

targeted deletion of MCS-R2 ameliorated the α/β -globin chain ratio to beneficial levels without perturbing erythroid differentiation or having detectable off-target events. If genome editing of MCS-R2 is to become a realistic therapeutic approach for β -thalassemia, then such an approach will be generally applicable to non- β^0/β^0 -genotype individuals in whom the endogenous output of β -globin is relatively high.

Even in individuals with β -thalassemia with non- β^0/β^0 genotypes, where BB305 has proven so effective, further increase in safety could be obtained by using a vector that can achieve a similar degree of therapeutic efficacy while minimizing the number of chromosomal integration events. This would be especially valuable for individuals with a possible increased predisposition to hematologic malignancies, as in those with sickle cell disease.^{48,49} Because optimal therapeutic benefits are likely to require a vector capable of completely restoring equimolar expression of α - and β -globin, the LV β -shz2 gene therapy vector may afford an improved benefit/risk ratio for all individuals with β -thalassemia regardless of genotype. Clinical trials of LV β -shz2, anticipated to be initiated shortly, should provide answers regarding the safety and efficacy of this approach for gene therapy of β -thalassemia.

MATERIALS AND METHODS

Lentiviral vector design, production, titration, and characterization in human cell lines

The LentiGlobin BB305 gene therapy vector has been described previously.⁵⁰ It is a self-inactivating (SIN), Tat-independent vector that contains a cytomegalovirus (CMV) promoter and enhancer instead of the HIV U3 region at the 5' long terminal repeat (LTR) and a deleted 3' U3 region and encodes the altered adult $\beta^{\text{A-T87Q}}$ -globin gene (Figure 1).⁵¹ The $\beta^{\text{A-T87Q}}$ -globin gene in the BB305 gene therapy vector features a 374-bp purine-rich deletion in IVS2, located between +580 and +953 of *HBB* ("GenBank: MG657341"), identified previously to increase viral titers.⁵² The IVS2 breakpoint site was used to insert the miR30-shRNA expression cassette flanked by approximately 125 bases 5' and 3' of the miR30 sequence to ensure β -globin-coupled shRNA expression in erythroid cells. This design mimics natural intronic miRNAs in protein-coding genes, which provide expression of the miRNAs and the protein-coding gene from a single transcript.⁵³ The miR30-shRNA expression cassette was selected for its well-characterized loop/bulge structure and accurate processing of shRNA/pre-miRNA ends.^{54,55}

A description of the cloning procedures is provided in Figure S1. Briefly, the miR30-shRNA cassette was amplified from the MSCV/LTRmiR30-PIGΔRI (LMP) vector.⁵⁶ Two partially complementary oligonucleotides (5'BP-miR30 and 3'BP-miR30; Table S1) with a 40-bp homologous sequence immediately flanking the deletion breakpoint of the β -globin intron 2 region was used to amplify the miR30-shRNA expression cassette. The resultant fragment was then used as the downstream megaprimer for the overlap extension PCR cloning strategy to insert the miR30-shRNA expression cassette into the β -globin IVS2 breakpoint site, which contained part of

β -globin exon 2, intron 2, exon 3, and 3' enhancer region cloned into the BamHI site of pBluescript II KS (+).⁵⁷ β -Globin intron 2 containing the miR30-shRNA cassette was then cloned into pBB305, replacing the existing BamHI fragment, and verified by sequencing. Using this approach, LV β -shRNA viral vector derivatives were created by incorporating shRNA sequences targeting EGFP (LV β -shGFP) and the negative control vector containing a scrambled shRNA sequence (LV β -shSCR) (Table S2). Oligonucleotides and primers used for cloning are listed in Table S1.

Lentiviral particles were produced by co-transfecting the lentiviral transfer vector with a packaging plasmid system as described previously.⁵⁸ The lentiviral titer was determined by transducing NIH/3T3 cells.⁵⁹ Lentiviral particles were evaluated in the MEL- β EGFP, K562, and HUDEP-2 cell lines as described previously.²² The down-regulation efficiency of EGFP expression was determined by measuring the median fluorescence intensity (MFI) by flow cytometry. Transduced K562 cells were incubated with hemin to induce erythroid differentiation. Human β^{A-T87Q} -globin expression was determined by intracellular antibody staining. β^0 -HUDEP-2 cells, containing biallelic β^0 -globin mutations, were created using CRISPR-Cas9 technology. Details can be found in the Supplemental materials and methods.

Human CD34⁺ transduction and culture

Human CD34⁺ cells were cultured in StemPro34 SFM (serum free medium, Thermo Fisher Scientific) supplemented with the human cytokines fms-related tyrosine kinase 3 ligand (hFlt3L), Stem Cell Factor (hSCF), and interleukin-3 (hIL-3) (at 50, 50, and 10 ng/mL, respectively; all from Miltenyi Biotec) in the presence of 20% serum substitute (BIT 9500, STEMCELL Technologies). After 7 days, erythropoietin (EPO) at 3 IU/mL was used to replace Flt3L, SCF, and IL-3 (medium 1). Alternatively, CD34⁺ cells were cultured in Iscove's modified Dubelcco's medium (IMDM) supplemented with SCF (100 ng/mL), IL-3 (5 ng/mL), and EPO (3 U/mL) from day 0, supplemented with SCF and EPO from day 8, and with EPO only from day 11 (medium 2). When indicated, CD34⁺ cells were transduced 24 h after the beginning of culture in medium containing protamine sulfate (8 μ g/mL) at MOIs between 2 and 10.

VCN determination

Genomic DNA from CD34⁺-derived cells was prepared from liquid culture or pooled colonies using the NucleoSpin Blood Kit (Macherey Nagel). VCNs per cell were determined by the delta-delta-Ct method ($\Delta\Delta$ Ct) method as described previously.⁶⁰ Primers and probes used for quantitative polymerase chain reaction (qPCR) are listed in Table S3.

RNA preparation and qRT-PCR

Total RNA was isolated using TRI Reagent solution or PureLink RNA Mini Kit (Thermo Fisher Scientific), and first-strand cDNA was synthesized using the SuperScript III First-Strand Synthesis System (Invitrogen) or EuroScript Reverse Transcriptase Core Kit (Eurogentec, Seraing, Belgium) according to the manufacturers' protocols. Gene

expression was quantified by quantitative reverse-transcriptase PCR (qRT-PCR), performed with gene-specific primers and probes (Table S4) and 2X qPCR Master Mix (Eurogentec) using the 7300 ABI Prism detection system. Relative expression of target genes was quantified based on the efficiency-corrected calculation method.⁶¹ For analysis of shRNA expression, first-strand cDNA synthesis was performed using specific stem-loop RT primers and subsequently analyzed by qPCR.^{62,63} For relative quantification of α -globin versus β -globin and γ -globin gene expression, the recombinant DNA plasmid pT7- $\alpha\beta\gamma$ containing *HBA*, *HBB*, and *HBG* cDNAs in tandem was used to generate standard curves.⁶⁴

Statistical analysis

Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad). A p value of less than 0.05, generated by a Student's t test, was considered statistically significant. The decreased rates of α/β -globin mRNA ratios and differences between groups using the exponential decay equation model (Supplemental materials and methods) were determined using GraphPad Prism 6.0.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.ymthe.2021.04.037>.

ACKNOWLEDGMENTS

We thank Drs. Ryo Kurita and Yukio Nakamura for providing the HUDEP-2 cell line. We also acknowledge Monash Pathology for assistance with HPLC and hemoglobin variant analysis of HUDEP-2 cells and the Fondation Générale de Santé (FGDS) and the Assistance Publique-Hôpitaux de Paris (AP-HP) for collecting and testing cord blood cells. This work was supported by the European Research Projects on Rare Diseases (GETHERTHAL); the European Commission; the National Health and Medical Research Council (NHMRC), Australia (Project Grant APP1147867); the Victorian Government's Operational Infrastructure Support Program; the Thalassaemia and Sickle Cell Society of Australia, the Thalassaemia Society of New South Wales; The Greek Conference; the National Research Council of Thailand (NRCT); the Thai Program Management Unit for Human Resources & Institutional Development, Research and Innovation (B05F630062); and Mahidol University (MRC-MGR 01/2563).

AUTHOR CONTRIBUTIONS

T.N., K.S.-F., M.G., B.M., E.P., P.L., and J.V. designed the experiments. T.N., K.S.-F., M.G., B.M., J.G., A.G., H.P.J.V., and H.Y.T. performed experiments. T.N., K.S.-F., M.G., B.M., J.G., A.G., H.P.J.V., H.Y.T., and E.P. analyzed data. G.G., S.S., S.F., and S.H. provided samples and resources. T.N., P.L., E.P., and J.V. wrote the manuscript. P.L., E.P., and J.V. conceptualized the idea and supervised the project.

DECLARATION OF INTERESTS

P.L. is a scientific founder and shareholder of bluebird bio, Inc. He is an inventor of awarded patents that cover the β^{A-T87Q} -globin gene and the BB305 LentiGlobin vector.

REFERENCES

- Higgs, D.R., Engel, J.D., and Stamatoyannopoulos, G. (2012). Thalassaemia. *Lancet* 379, 373–383.
- Weatherall, D.J., and Clegg, J.B. (2001). Inherited haemoglobin disorders: an increasing global health problem. *Bull. World Health Organ.* 79, 704–712.
- Voon, H.P., and Vadolas, J. (2008). Controlling alpha-globin: a review of alpha-globin expression and its impact on beta-thalassemia. *Haematologica* 93, 1868–1876.
- Grosveld, F., van Assendelft, G.B., Greaves, D.R., and Kollias, G. (1987). Position-independent, high-level expression of the human beta-globin gene in transgenic mice. *Cell* 51, 975–985.
- Magrin, E., Miccio, A., and Cavazzana, M. (2019). Lentiviral and genome-editing strategies for the treatment of β -hemoglobinopathies. *Blood* 134, 1203–1213.
- Sii-Felice, K., Negre, O., Brendel, C., Tubsuban, A., Morel-À-F'Huissier, E., Filardo, C., and Payen, E. (2020). Innovative Therapies for Hemoglobin Disorders. *BioDrugs* 34, 625–647.
- Imren, S., Payen, E., Westerman, K.A., Pawliuk, R., Fabry, M.E., Eaves, C.J., Cavilla, B., Wadsworth, L.D., Beuzard, Y., Bouhassira, E.E., et al. (2002). Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. *Proc. Natl. Acad. Sci. USA* 99, 14380–14385.
- Pawliuk, R., Westerman, K.A., Fabry, M.E., Payen, E., Tighe, R., Bouhassira, E.E., Acharya, S.A., Ellis, J., London, I.M., Eaves, C.J., et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. *Science* 294, 2368–2371.
- Kwiatkowski, J.L., Thompson, A.A., Rasko, J.E.J., Hongeng, S., Schiller, G.J., Anurathapan, U., et al. (2019). Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β -Thalassemia in the Northstar (HGB-204) Study. *Blood* 134, 4628.
- Lal, A., Locatelli, F., Kwiatkowski, J.L., Kulozik, A.E., Yannaki, E., Porter, J.B., et al. (2019). Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β -Thalassemia and Either a β^0 or IVS-1-110 Mutation at Both Alleles of the HBB Gene. *Blood* 134, 815.
- Thompson, A.A., Walters, M.C., Kwiatkowski, J., Rasko, J.E.J., Ribeil, J.A., Hongeng, S., Magrin, E., Schiller, G.J., Payen, E., Semeraro, M., et al. (2018). Gene Therapy in Patients with Transfusion-Dependent β -Thalassemia. *N. Engl. J. Med.* 378, 1479–1493.
- Thompson, A.A., Walters, M.C., Kwiatkowski, J.L., Hongeng, S., Porter, J.B., Sauer, M.G., et al. (2019). Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β -Thalassemia and Non- β^0/β^0 Genotypes. *Blood* 134, 3543.
- Magrin, E., Semeraro, M., Magnani, A., Puy, H., Miccio, A., Hebert, N., et al. (2019). Results from the Completed Hgb-205 Trial of Lentiglobin for β -Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy. *Blood* 134, 3358.
- Ribeil, J.A., Hacin-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017). Gene Therapy in a Patient with Sickle Cell Disease. *N. Engl. J. Med.* 376, 848–855.
- Harrison, C. (2019). First gene therapy for β -thalassaemia approved. *Nat. Biotechnol.* 37, 1102–1103.
- Thalassaemia International Federation (2020). Clinical trial updates: ZYNTEGLO (ex-Lentiglobin) for patients with TDT, <https://thalassaemia.org.cy/publications/clinical-trial-updates/gene-therapy/>.
- Marktel, S., Scaramuzza, S., Cicalese, M.P., Giglio, F., Galimberti, S., Lidonnicci, M.R., Calbi, V., Assanelli, A., Bernardo, M.E., Rossi, C., et al. (2019). Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β -thalassaemia. *Nat. Med.* 25, 234–241.
- Mettananda, S., Gibbons, R.J., and Higgs, D.R. (2015). α -Globin as a molecular target in the treatment of β -thalassaemia. *Blood* 125, 3694–3701.
- Sripichai, O., Munkongdee, T., Kumkhaek, C., Svasti, S., Winichagoon, P., and Fuchareon, S. (2008). Coinheritance of the different copy numbers of alpha-globin gene modifies severity of beta-thalassemia/Hb E disease. *Ann. Hematol.* 87, 375–379.
- Thein, S.L. (2008). Genetic modifiers of the beta-haemoglobinopathies. *Br. J. Haematol.* 141, 357–366.
- Voon, H.P., Warden, H., and Vadolas, J. (2008). siRNA-mediated reduction of alpha-globin results in phenotypic improvements in beta-thalassemic cells. *Haematologica* 93, 1238–1242.
- Chan, K.S., Xu, J., Warden, H., McColl, B., Orkin, S., and Vadolas, J. (2012). Generation of a genomic reporter assay system for analysis of γ - and β -globin gene regulation. *FASEB J.* 26, 1736–1744.
- McColl, B., Kao, B.R., Lourthai, P., Chan, K., Warden, H., Roosjen, M., Delagneau, O., Gearing, L.J., Blewitt, M.E., Svasti, S., et al. (2014). An in vivo model for analysis of developmental erythropoiesis and globin gene regulation. *FASEB J.* 28, 2306–2317.
- Kurita, R., Suda, N., Sudo, K., Miharada, K., Hiroyama, T., Miyoshi, H., Tani, K., and Nakamura, Y. (2013). Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. *PLoS ONE* 8, e59890.
- Miccio, A., Cesari, R., Lotti, F., Rossi, C., Sanvito, F., Ponzoni, M., Routledge, S.J., Chow, C.M., Antoniou, M.N., and Ferrari, G. (2008). In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. *Proc. Natl. Acad. Sci. USA* 105, 10547–10552.
- Puthenveetil, G., Scholes, J., Carbonell, D., Qureshi, N., Xia, P., Zeng, L., Li, S., Yu, Y., Hiti, A.L., Yee, J.K., and Malik, P. (2004). Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. *Blood* 104, 3445–3453.
- Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J.L., Rivella, S., and Cavazzana, M. (2019). Gene therapy of hemoglobinopathies: progress and future challenges. *Hum. Mol. Genet.* 28 (R1), R24–R30.
- Fehse, B., Kustikova, O.S., Bubenheim, M., and Baum, C. (2004). Pois(s)on—it's a question of dose. *Gene Ther.* 11, 879–881.
- Arumugam, P.I., Scholes, J., Perelman, N., Xia, P., Yee, J.K., and Malik, P. (2007). Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (CHS4) insulator element. *Mol. Ther.* 15, 1863–1871.
- Lisowski, L., and Sadelain, M. (2007). Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. *Blood* 110, 4175–4178.
- Ramezani, A., Hawley, T.S., and Hawley, R.G. (2008). Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. *Stem Cells* 26, 3257–3266.
- Romero, Z., Urbinati, F., Geiger, S., Cooper, A.R., Wherley, J., Kaufman, M.L., Hollis, R.P., de Assin, R.R., Senadheera, S., Sahagian, A., et al. (2013). β -globin gene transfer to human bone marrow for sickle cell disease. *J. Clin. Invest.* 123, 3317–3330.
- Ronen, K., Negre, O., Roth, S., Colomb, C., Malani, N., Denaro, M., Brady, T., Fusil, F., Gillet-Legrand, B., Hehir, K., et al. (2011). Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β -thalassaemia. *Mol. Ther.* 19, 1273–1286.
- Urbinati, F., Arumugam, P., Higashimoto, T., Perumbeti, A., Mitts, K., Xia, P., and Malik, P. (2009). Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. *Mol. Ther.* 17, 1527–1536.
- Wainscoat, J.S., Thein, S.L., and Weatherall, D.J. (1987). Thalassaemia intermedia. *Blood Rev.* 1, 273–279.
- Cappellini, M.D., and Motta, I. (2017). New therapeutic targets in transfusion-dependent and -independent thalassaemia. *Hematology (Am. Soc. Hematol. Educ. Program)* 2017, 278–283.
- Thein, S.L. (2018). Molecular basis of β thalassaemia and potential therapeutic targets. *Blood Cells Mol. Dis.* 70, 54–65.
- Voon, H.P., Warden, H., and Vadolas, J. (2007). Co-inheritance of alpha- and beta-thalassaemia in mice ameliorates thalassaemic phenotype. *Blood Cells Mol. Dis.* 39, 184–188.
- Samakoglu, S., Lisowski, L., Budak-Alpdogan, T., Usachenko, Y., Acuto, S., Di Marzo, R., Maggio, A., Zhu, P., Tisdale, J.F., Rivière, I., and Sadelain, M. (2006). A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. *Nat. Biotechnol.* 24, 89–94.
- Guda, S., Brendel, C., Renella, R., Du, P., Bauer, D.E., Canver, M.C., Grenier, J.K., Grimson, A.W., Kamran, S.C., Thornton, J., et al. (2015). miRNA-embedded

- shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. *Mol. Ther.* 23, 1465–1474.
41. Wilber, A., Hargrove, P.W., Kim, Y.S., Riberdy, J.M., Sankaran, V.G., Papanikolaou, E., Georgomanoli, M., Anagnou, N.P., Orkin, S.H., Nienhuis, A.W., and Persons, D.A. (2011). Therapeutic levels of fetal hemoglobin in erythroid progeny of β -thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. *Blood* 117, 2817–2826.
 42. Brendel, C., Guda, S., Renella, R., Bauer, D.E., Canver, M.C., Kim, Y.J., Heeney, M.M., Klatt, D., Fogel, J., Milsom, M.D., et al. (2016). Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. *J. Clin. Invest.* 126, 3868–3878.
 43. Brendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020). Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy. *Mol. Ther. Methods Clin. Dev.* 17, 589–600.
 44. Esrick, E.B., Achebe, M., Armant, M., Bartolucci, P., Ciuculescu, M.F., Daley, H., et al. (2019). Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing. *Blood* 134, LBA-5.
 45. Patsali, P., Papasavva, P., Stephanou, C., Christou, S., Sitarou, M., Antoniou, M.N., Lederer, C.W., and Kleanthous, M. (2018). Short-hairpin RNA against aberrant *HBB*^{IVSI-110(G>A)} mRNA restores β -globin levels in a novel cell model and acts as mono- and combination therapy for β -thalassemia in primary hematopoietic stem cells. *Haematologica* 103, e419–e423.
 46. Papadaki, M., and Vassilopoulos, G. (2013). Decrease of alpha-chains in beta-thalassemia. *Thalassemia Reports* 3, e40.
 47. Mettananda, S., Fisher, C.A., Hay, D., Badat, M., Quek, L., Clark, K., Hublitz, P., Downes, D., Kerry, J., Gosden, M., et al. (2017). Editing an α -globin enhancer in primary human hematopoietic stem cells as a treatment for β -thalassemia. *Nat. Commun.* 8, 424.
 48. Brunson, A., Keegan, T.H.M., Bang, H., Mahajan, A., Paulukonis, S., and Wun, T. (2017). Increased risk of leukemia among sickle cell disease patients in California. *Blood* 130, 1597–1599.
 49. Kaiser, J. (2021). Gene therapy trials for sickle cell disease halted after two patients develop cancer. *ScienceMag*, February 16, 2021, <https://www.sciencemag.org/news/2021/02/gene-therapy-trials-sickle-cell-disease-halted-after-two-patients-develop-cancer>.
 50. Negre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., de Dreuzy, E., Finer, M., et al. (2015). Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β -thalassemia and sickle cell disease. *Curr. Gene Ther.* 15, 64–81.
 51. Negre, O., Eggimann, A.V., Beuzard, Y., Ribeil, J.A., Bourget, P., Borwornpinyo, S., Hongeng, S., Haccin-Bey, S., Cavazzana, M., Leboulch, P., and Payen, E. (2016). Gene Therapy of the β -Hemoglobinopathies by Lentiviral Transfer of the β (A(T87Q))-Globin Gene. *Hum. Gene Ther.* 27, 148–165.
 52. Leboulch, P., Huang, G.M., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y., and London, I.M. (1994). Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. *EMBO J.* 13, 3065–3076.
 53. Du, G., Yonekubo, J., Zeng, Y., Osisami, M., and Frohman, M.A. (2006). Design of expression vectors for RNA interference based on miRNAs and RNA splicing. *FEBS J.* 273, 5421–5427.
 54. Gu, S., Jin, L., Zhang, Y., Huang, Y., Zhang, F., Valdmanis, P.N., and Kay, M.A. (2012). The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. *Cell* 151, 900–911.
 55. Stegmeier, F., Hu, G., Rickles, R.J., Hannon, G.J., and Elledge, S.J. (2005). A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. *Proc. Natl. Acad. Sci. USA* 102, 13212–13217.
 56. Dickens, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., and Lowe, S.W. (2005). Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. *Nat. Genet.* 37, 1289–1295.
 57. Bryksin, A.V., and Matsumura, I. (2010). Overlap extension PCR cloning: a simple and reliable way to create recombinant plasmids. *Biotechniques* 48, 463–465.
 58. Sii-Felice, K., Castillo Padilla, J., Relouzat, F., Cheuzeville, J., Tantawet, S., Maoouche, L., Le Grand, R., Leboulch, P., and Payen, E. (2019). Enhanced Transduction of *Macaca fascicularis* Hematopoietic Cells with Chimeric Lentiviral Vectors. *Hum. Gene Ther.* 30, 1306–1323.
 59. Payen, E., Colomb, C., Negre, O., Beuzard, Y., Hehir, K., and Leboulch, P. (2012). Lentivirus vectors in β -thalassemia. *Methods Enzymol.* 507, 109–124.
 60. Negre, O., Fusil, F., Colomb, C., Roth, S., Gillet-Legrand, B., Henri, A., Beuzard, Y., Bushman, F., Leboulch, P., and Payen, E. (2011). Correction of murine β -thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion. *Blood* 117, 5321–5331.
 61. Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 29, e45.
 62. Schmittgen, T.D., Lee, E.J., Jiang, J., Sarkar, A., Yang, L., Elton, T.S., and Chen, C. (2008). Real-time PCR quantification of precursor and mature microRNA. *Methods* 44, 31–38.
 63. Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z., Lee, D.H., Nguyen, J.T., Barbisin, M., Xu, N.L., Mahavakar, V.R., Andersen, M.R., et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* 33, e179.
 64. Tubsuwan, A., Munkongdee, T., Jearawiriyapaisarn, N., Boonchoy, C., Winichagoon, P., Fucharoen, S., and Svasti, S. (2011). Molecular analysis of globin gene expression in different thalassaemia disorders: individual variation of β (E) pre-mRNA splicing determine disease severity. *Br. J. Haematol.* 154, 635–643.